Shawn M. Gage, PA-C
Founder
Director of Clinical Operations
InnAVasc Medical, Inc.
Durham, NC, United States
Adjunct Faculty, Duke University PA Program

An Immediate Use Dialysis Graft Designed to Prevent Needle-Related Complications

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Disclosure

Shawn M. Gage, PA-C

.....

I have the following conflicts of interest to report:

- ✓ Co-inventor of InnAVasc technology
- ✓ Ownership in InnAVasc
- ✓ Shareholder in InnAVasc
- ✓ Employed by InnAVasc
- ✓ Receipt of grants/research support from NIH and NSF

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Current dialysis grafts have many pitfalls

Not Reliable

Lack of Durability

Preventable Complications

*Contribute to the **$2.9B** spent annually on malfunctioning vascular access*

Challenging

...ation Required




Standard Graft
© 2016 Duke Surgery and Lauren Halligan


Standard Graft
Injury
© 2016 Duke Surgery and Lauren Halligan
Standard Graft
Injury
© 2016 Duke Surgery and Lauren Halligan
© 2016 Duke Surgery and Lauren Halligan
© 2016 Duke Surgery and Lauren Halligan

What is needed?
A **reliable** access that can be used **immediately**



Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Key InnAVasc device features

Designed to address complications faced with current grafts



1. Cannulation Chamber
   Durable
2. Back Plate
   Safe
3. Cannulation Ridge
   Functional
4. Self-sealing Material
   Immediate Use

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use


INNAVASC
Dialysis Device
© 2016 Duke Surgery and Lauren Halligan

Current Clinical Feasibility Study

- 7 clinical sites in the US
- Enrollment began Jan 2, 2019
- 26 patients enrolled/implanted
  - 13 Looped, 13 Straight



Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Chamber Performance to Date

- Half of subjects have had graft used for HD POD#1
- Majority have had the graft used within 2-7 days
- Percutaneous interventions have been performed through the chamber within 1 week of implant
- No needle-related complications have been reported to date
- First 3 subjects have reached 4 months of follow up

Aneurysmal AVF – Difficulty with cannulation – No perm cath

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Immediately post aneurysmal AVF resection and InnAVasc Graft placement



Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use



Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use



Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use



Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Immediate Post-op

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Large, Aneurysmal AVF replaced with InnAVasc Graft

Used POD#1

NO Perm Cath Required

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use

Conclusion

- Immediate access with the InnAVasc Graft appears feasible and safe
- Appears to be working to prevent needle related injuries/problems
- Appears to be working to promote reliable access zones for cannulation
- Early percutaneous access for interventions appears feasible and safe
  - Accommodates standard sizes 6F-8F
- Information from this study will inform ongoing development

Disclaimer: The InnAVasc Vascular Access Graft has not received regulatory clearance & is therefore not currently available for commercial use



VASA is on Social Media!

Check us out at:

- **Twitter:** *@vasamd*
  #VASA2019
- **Facebook**
- **LinkedIn**